Oxybutynin extended release and tolterodine immediate release : a health economic comparison.

Oxybutynin extended release and tolterodine immediate release : a health economic comparison. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Oxybutynin extended release and tolterodine immediate release : a health economic comparison. Abstract Text:

D Getsios,J J Caro,K J Ishak,W El-Hadi,K Payne,M O'connel,D Albrecht,W Feng,D Dubois,

OBJECTIVE: To evaluate the cost-effectiveness of a new extended-release (XL) formulation of oxybutynin relative to tolterodine immediate release (IR), currently the most prescribed treatment for overactive bladder in the UK. METHODS: A state-transition model was developed to compare outcomes over 1 year. Effectiveness and treatment persistence data were derived from the OBJECT (Overactive Bladder: Judging Effective Control and Treatment) study, a 3-month clinical trial comparing oxybutynin XL 10 mg/day with tolterodine IR 4 mg/day. The daily costs of oxybutynin XL and tolterodine IR were pound0.82 and pound1.04, respectively. These data and information from the literature were used to project outcomes beyond the trial time. Severity-specific incontinence cost profiles were developed for the UK (2002 costings). RESULTS: After 1 year, 3.1 more patients per 100 treated attained complete continence with oxybutynin XL compared with tolterodine IR, and 5.6% more had less than seven incontinent episodes per week. Over 1 year, patients receiving oxybutynin XL had almost 17 additional incontinence-free days and 95 fewer incontinent episodes. Estimated costs were pound86 lower per patient with oxybutynin XL. If drugs are priced equally, savings decrease to pound21 per patient. Oxybutynin XL maintains its advantage over wide ranges of inputs, and outcomes are similar if analyses are limited to 3 months. CONCLUSION: Base-case analyses suggest that oxybutynin XL provides better effectiveness than tolterodine IR and reduces costs. Results indicate that oxybutynin XL is the dominant therapeutic option under a wide range of alternative inputs and assumptions.

Oxybutynin extended release and tolterodine immediate release : a health economic comparison. Publishing Authors By Initials

D Getsios,JJ Caro,KJ Ishak,W El-Hadi,K Payne,M O'connel,D Albrecht,W Feng,D Dubois,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Oxybutynin extended release and tolterodine immediate release : a health economic comparison. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical drug investigation

VOLUME: 24

Page Numbers: 81-8

Journal Abbreviation:

ISSN: 1173-2563

DAY: 22

MONTH: 05

YEAR: 2004

Oxybutynin extended release and tolterodine immediate release : a health economic comparison. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9504817

Oxybutynin extended release and tolterodine immediate release : a health economic comparison. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Oxybutynin extended release and tolterodine immediate release : a health economic comparison. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Oxybutynin extended release and tolterodine immediate release : a health economic comparison.

AFFILIATION: Caro Research Institute, Hammonds Plains, Nova Scotia, Canada.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Drug Investig

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Oxybutynin extended release and tolterodine immediate release : a health economic comparison Related Publications

• A biomechanical model of the pelvic cavity: first steps.
• A novel approach to clinical-radiological correlations: Anatomo-Clinical Overlapping Maps (AnaCOM): method and validation.
• A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch.
• Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study.
• Benchmarking in the eighteenth century.
• Bungendore health impact assessment: urban development in a rural setting.
• Clinical diagnostic criteria for dementia associated with Parkinson's disease.
• Cross-border referral for early breast cancer: an analysis of radiation fractionation patterns.
• Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression.
• Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: A guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention.
• Direction of persistent ischemic mitral jet after restrictive valve annuloplasty: Implication for interpretation of perioperative echocardiography.
• Effects of acute exposure to aluminum on cognition in humans.
• Encephalitis following Mycoplasma pneumonia (2007: 6b). Acute disseminated encephalomyelitis.
• Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells.
• High pretransplantation soluble CD30 levels: impact in renal transplantation.
• Hypoxia-inducible Factor Mediates Hypoxic and Tumor Necrosis Factor {alpha}-induced Increases in Tumor Necrosis Factor-{alpha} Converting Enzyme/ADAM17 Expression by Synovial Cells.
• Is PD-MCI a useful concept?
• Measurement of eicosanoids in cancer tissues.
• NSAIDs and cancer prevention: targets downstream of COX-2.
• Noninvasive cardiac output monitoring (NICOM): a clinical validation.
• Oxybutynin extended release and tolterodine immediate release : a health economic comparison.
• Polarization-sensitive full-field optical coherence tomography.
• Pure topographical disorientation following a right forceps major of the splenium lesion: a case study.
• Ras up-regulation of cyclooxygenase-2.
• Synthesis and biological evaluation of potential bisubstrate inhibitors of protein farnesyltransferase. Design and synthesis of functionalized imidazoles.
• Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
• The needs of rural and urban young, middle-aged and older adults with a serious mental illness.
• Thiol-disulphide oxidoreductase modules in the low-GC Gram-positive bacteria.
• [Frontotemporal dementia]
• [In Process Citation]